- Title
- Anthracycline-induced cardiotoxicity: time to focus on cardioprotection again
- Creator
- Croft, A. J.; Ngo, D. T. M.; Sverdlov, A. L.
- Relation
- Heart Lung and Circulation Vol. 28, Issue 10, p. 1454-1456
- Publisher Link
- http://dx.doi.org/10.1016/j.hlc.2019.08.002
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2019
- Description
- Anthracyclines have been in clinical use for decades due to their anti-neoplastic effects in many cancers including breast cancer, leukaemia, lymphoma, sarcoma, lung cancer and mul-tiple myeloma, however the effective use of these agents is limited by the danger of cardiotoxicity [1]. Incidence of car-diotoxicity in patients treated with anthracyclines varies according to cardiotoxicity definition, but has been reported as high as 26% for heart failure and 36% for left ventricular dysfunction [2,3], with the major predicting factor being anthracycline cumulative dose. Conventionally, anthracy-cline-induced cardiomyopathy is usually detected/monitored by assessing changes in left ventricular function using cardiac imaging (echocardiography, nuclear medicine or [magnetic resonance imaging] MRI) along with measurement of bio-markers such as cardiac troponin T [1]. With improvements in the long-term cancer survival, the cardiotoxic effects of anthracyclines are becoming an increasingly relevant problem for cancer survivors and health care system.
- Subject
- cardio-oncology; cardiotoxicity; anthracyclines; cardioprotection
- Identifier
- http://hdl.handle.net/1959.13/1414366
- Identifier
- uon:36732
- Identifier
- ISSN:1443-9506
- Language
- eng
- Reviewed
- Hits: 1053
- Visitors: 1050
- Downloads: 0